STZ - Constellation Brands, Inc.

NYSE - NYSE Delayed Price. Currency in USD
183.90
+2.64 (+1.46%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close181.26
Open181.76
Bid176.50 x 900
Ask215.00 x 800
Day's Range181.76 - 184.27
52 Week Range150.37 - 233.00
Volume2,272,441
Avg. Volume1,877,865
Market Cap35.021B
Beta (3Y Monthly)1.04
PE Ratio (TTM)10.47
EPS (TTM)17.57
Earnings DateJun 28, 2019
Forward Dividend & Yield3.00 (1.63%)
Ex-Dividend Date2019-05-09
1y Target Est221.77
Trade prices are not sourced from all markets
  • TheStreet.com15 hours ago

    Constellation Brands Looking Wobbly as Beer Demand Fizzles

    are expected Friday, and the beverage company will likely be held hostage to slowing beer demand, according to Jim Cramer on "Mad Money" Friday. In this daily bar chart of STZ, below, we can see that prices rallied from January to late April. The math-based indicators -- also known as the moving averages -- were positive.

  • Benzinga20 hours ago

    Canopy Growth CEO Looks To The 'Pharmaceutical World' After String Of M&A Deals

    Canopy bought at least a dozen smaller cannabis producers over the past year, but the string of acquisitions has come to an end, Linton told the publication. Flush with billions of dollars from Constellation Brands, Inc. (NYSE: STZ)'s investment, the cannabis company is now "more interested in what exists in the pharmaceutical world," he said. Need more cannabis news?

  • TheStreet.com2 days ago

    3 Big Earnings Reports to Watch This Week

    has a five-year track record of solid revenue growth, improved margins, and strong profitability. More recently, though, the stock is getting pulled into the ongoing trade war between the United States and China. Earnings per share increased 51% in fiscal 2018 (May) to $16.79 per diluted share.

  • Benzinga2 days ago

    Cramer On Cannabis: Innovative Industrial Won't 'Let You Sleep Soundly,' Constellation A Safer Bet

    Friday was a difficult day for cannabis companies after Canopy Growth Corp (NYSE: CGC )'s earnings report showed a quarter-over-quarter decline in Canadian recreational usage, CNBC's Jim Cramer said during ...

  • Constellation Brands Earnings: What to Watch
    Motley Fool2 days ago

    Constellation Brands Earnings: What to Watch

    Investors have some big questions heading into the beer giant's upcoming earnings report.

  • Zacks2 days ago

    Stocks Rise for Third Straight Week

    Stocks Rise for Third Straight Week

  • Barrons.com3 days ago

    Micron, Lennar, FedEx and More Stocks to Watch This Week

    Earnings reports also from Walgreens and Nike, and economic data on consumer confidence, GDP, and more. And the G-20 meeting will cap off the week.

  • 3 Things to Watch in the Stock Market This Week
    Motley Fool3 days ago

    3 Things to Watch in the Stock Market This Week

    Look for Nike, Constellation Brands, and McCormick stocks to make big moves over the next few trading days in advance of earnings reports late in the week.

  • Investing.com3 days ago

    Economic Calendar - Top 5 Things to Watch This Week

    Investing.com - Market watchers will be looking ahead to a meeting between U.S. President Donald Trump and China's President Xi Jinping this week amid hopes for a thaw in trade relations, even if it alters expectations for Federal Reserve rate cuts.

  • TheStreet.com5 days ago

    At Canopy Growth it's a Question of Expansion vs. Value

    is causing strife for investors Friday, as quarterly losses widened substantially in the fiscal fourth quarter of 2019. It should not come as too much of a shock to investors, as the share pricing has been highly speculative from the start. If investors want meaningful earnings behind the stock price, it seems they'll be waiting a while.

  • Motley Fool5 days ago

    Stock Market News: Pot Losses Hit Constellation Brands; Medtronic Delivers Dividends

    Stocks kept gaining ground on Friday morning.

  • TheStreet.com5 days ago

    Should Investors Buy the Dip in Canopy Growth Stock?

    Despite a sharp decline in shares of Canopy Growth after disappointing earnings results on Wednesday evening, many analysts following the stock believe the long-term outlook should provide confidence in a dip buying opportunity on CGC.

  • TheStreet.com5 days ago

    Canopy Growth Shares Slump After Q4 Earnings; Canadian Pot Sales Slow

    shares traded sharply lower Friday after the Canadian cannabis group posted a wider-than-expected fourth quarter loss and said recreational sales slowed from the previous three month period. Canopy Growth said its loss for the three months ending in March came in at C$0.98 per share, well shy of the C$0.32 loss expected by analysts that cover the cannabis growing group, taking its full-year loss to C$670 million ($507.87 million). Group revenues, however, rose 191% to C$226.3 million for the full year, the company said, with the fourth quarter tally coming in at $94.1 million, just ahead of the Street's C$92.6 million forecast.

  • 3 Earnings Reports to Watch Next Week
    InvestorPlace5 days ago

    3 Earnings Reports to Watch Next Week

    Editor's note: InvestorPlace's Earnings Reports to Watch is updated weekly. Please check back next week for our latest earnings picks.The earnings calendar is surprisingly full next week. Typically, late June is a quiet time for the market. But several major companies in several key sectors will deliver earnings reports next week.Most notably, investors should be able to get a read on the consumer packaged goods sector. Conagra Brands (NYSE:CAG), McCormick (NYSE:MKC), Constellation Brands (NYSE:STZ,NYSE:STZ.B), and General Mills (NYSE:GIS) all release earnings reports next week. The market will get some good data on the struggling supplier side of that industry after decent, but unspectacular results from retailer Kroger (NYSE:KR) this week.InvestorPlace - Stock Market News, Stock Advice & Trading TipsElsewhere, FedEx (NYSE:FDX) delivers its fiscal fourth-quarter results on Tuesday afternoon. FedEx isn't quite the economic bellwether it once was, but its take on the macro economy still will be worth noting. And investors in United Parcel Service (NYSE:UPS) no doubt will be watching closely as the two incumbents try and manage rising pressure from Amazon.com (NASDAQ:AMZN). * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 Reports from KB Home (NYSE:KBH) and BlackBerry (NYSE:BB) also look important. Overall, there's a decent amount of news coming ahead of a holiday week. But even those reports aren't the most important to watch next week -- which shows just how much is going on. Before going on vacation, investors need to pay attention to these three key earnings reports next week: Micron (MU)Source: Shutterstock Earnings Report Date: Tuesday, June 25, after market closeFew companies outside of Micron (NASDAQ:MU) seem more in need of a good earnings report. And excluding retail, few sectors need a dose of optimism more than semiconductors. Hopes for a second-half recovery seem to have dimmed. Commentary after Broadcom (NASDAQ:AVGO) earnings this week are the latest signal that a chip rebound isn't coming until 2020 at the earliest.For Micron, memory prices still are headed in the wrong direction, but the question remains how long that will last. As such, commentary from management on Tuesday afternoon may be more important than the actual numbers.It will also be interesting to see how aggressive the company was in buying back MU stock given a $10 billion repurchase authorization announced last year. Did the company put its money where its proverbial mouth has been?MU stock does look attractive at the lows, in part because it looks so cheap. But that valuation exists because market participants believe earnings declines will continue for some time to come. If Micron can convince those investors otherwise, MU stock will rise. And it will likely bring other chip stocks -- and their suppliers -- along for the ride. Walgreens Boots Alliance (WBA)Source: Mike Mozart via FlickrEarnings Report Date: Thursday, June 27, before market openThen again, it could be worse for chip stocks; they could be pharmacies. Walgreens Boots Alliance (NASDAQ:WBA) heads into Thursday's earnings report just off a five-year low. It's not alone. CVS Health (NYSE:CVS) touched a six-year low last month. Rite Aid (NYSE:RAD) is in a similar spot.Here, too, both the stock and the industry desperately need some good news from earnings. But there's not a lot of reason to expect that good news is on the way. Front-end sales trends have been negative across the industry of late, with no sign of a bottom. Pressures on the pharmacy side -- fewer generics and higher drug costs -- aren't going anywhere. And as I wrote in April, Walgreens' execution has left quite a bit to be desired as well. * 5 Boring Stocks to Buy This Summer WBA stock is cheap, and investors might see this as the point of maximum pessimism. But that case could have made for the last few quarters; none of those earnings reports have changed the broader trend here. If Walgreens can deliver, pharmacy stocks can rally. At the moment, however, that seems like a big ask. Nike (NKE)Source: Shutterstock Earnings Report Date: Thursday, June 27, after market closeEarnings reports from Nike (NYSE:NKE) are always interesting. The sneaker giant is a barometer for consumer confidence, given its high-dollar and somewhat discretionary offerings. NKE stock itself generally doesn't move all that much after earnings, but its numbers and commentary can have an impact across the apparel and footwear industries.Thursday afternoon's report seems a bit more interesting than usual. As Luke Lango noted, Nike is one of the stocks with the largest exposure to trade war concerns. That's true on the cost front, given how many Nike products are manufactured in that country. But as Lango noted, Nike also gets 15% of its sales from Greater China.And so Nike represents a test case for the impact of U.S.-China relations at the moment. Are Chinese consumers shunning U.S. brands --even Nike, one of their perennial favorites? Can tariff impacts on the cost side be offset? If not, how big is the impact?At the moment, it looks like the trade war is a long way from ending. Investors trying to prepare for the 'new normal' should take a close look at Nike earnings to understand what that new environment might look like.As of this writing, Vince Martin has no positions in any securities mentioned.Compare Brokers The post 3 Earnings Reports to Watch Next Week appeared first on InvestorPlace.

  • Constellation Brands (STZ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks5 days ago

    Constellation Brands (STZ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Constellation Brands (STZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What's in Store for Constellation Brands' (STZ) Q1 Earnings?
    Zacks5 days ago

    What's in Store for Constellation Brands' (STZ) Q1 Earnings?

    Constellation Brands' (STZ) constant brand-building efforts, acquisitions and pipeline of innovations are encouraging. However, its soft wine & spirits business remains a headwind.

  • MarketWatch5 days ago

    Corona-parent Constellation Brands to record $106 million loss as its share of Canopy Growth's losses

    Shares of Constellation Brands Inc. eased 0.1% in morning trading Friday, after the owner of Corona and Modela beer and Svedka vodka brands disclosed that it's share of Canopy Growth Corp.'s fiscal fourth-quarter losses comes to $106 million, or $78.2 million after including tax benefits. The company, which owns a 35.8% stake in Canada-based cannabis company Canopy, said it recognizes equity in earnings from its equity-method investment in Canopy on a 2-month lag. Canopy reported late Thursday a fourth-quarter net loss of C$323.4 million ($244.8 million). Constellation said it expects to record those losses in its fiscal first-quarter, which ended in May. Constellation's stock has gained 9.6% over the past three months, while the U.S.-listed shares of Canopy have shed 10.0% and the S&P 500 has gained 3.4%.

  • Here's Why Monster Beverage (MNST) is a Hot Investment Pick
    Zacks5 days ago

    Here's Why Monster Beverage (MNST) is a Hot Investment Pick

    Monster Beverage (MNST) is benefiting from brand strength, constant product launches and innovations. Further, the company is on track with growth in its international markets.

  • Will Teetotal Millennials Spell Doomsday for Beer Bigwigs?
    Zacks5 days ago

    Will Teetotal Millennials Spell Doomsday for Beer Bigwigs?

    When it comes to consuming alcohol, millennials prefer drinking wines, clean spirits and wellness beer.

  • These Billion-Dollar Pot Stocks Are Buyout Candidates
    Motley Fool5 days ago

    These Billion-Dollar Pot Stocks Are Buyout Candidates

    Three marijuana stocks worth more than $1 billion that look more like acquisition targets than acquirers.

  • TheStreet.com5 days ago

    Iran, Trump, Canopy Growth, Slack, Zion Williamson - 5 Things You Must Know

    U.S. stock futures declined on Friday following a report that President Donald Trump ordered, and then rescinded, an airstrike on military installations in Iran. The planned strike, which was reported by The New York Times, was meant to take place early Friday in response to the downing on Thursday of a U.S. drone patrolling the Strait of Hormuz. Trump had warned that Iran made a "big mistake" and warned of consequences to follow, but appeared to pull back from executing a military response only hours before U.S. jets were set to take off.

  • TheStreet.com5 days ago

    Canopy Growth Tops Revenue Estimates, Warns of 'Material Non-Cash Charge'

    The Canadian based medical and recreational marijuana grower reported net revenue of CA$94.1 million ($71.4 million) vs. CA$22.8 million ($17.3 million) a year ago. Other cannabis-related companies were generally higher Thursday ahead of the Canopy report.

  • Constellation Brands (STZ) Gains But Lags Market: What You Should Know
    Zacks6 days ago

    Constellation Brands (STZ) Gains But Lags Market: What You Should Know

    Constellation Brands (STZ) closed the most recent trading day at $185.74, moving +0.77% from the previous trading session.

  • The Short-Term Earnings Numbers for CGC Stock Aren’t Most Important
    InvestorPlace6 days ago

    The Short-Term Earnings Numbers for CGC Stock Aren’t Most Important

    Canopy Growth Corporation (NASDAQ: CGC) is close to breaking out above the $45 level after bouncing off the sub-$40 low at the start of June. The market will look to the CGC stock fourth-quarter earnings report after the market close on June 20 before making the next big move. What will Canopy's earnings report look like? Should investors look beyond the quarterly results and stay on course for at least the next few years?Source: Shutterstock Fourth-Quarter Earnings ExpectationsAnalysts expect CGC stock will report a loss per share of 17 cents -- compared to last quarters earnings per share of 22 cents CAD ( approximately 17 U.S. cents). This despite a forecasted threefold revenue increase to $90.1 million CAD from the year ago quarter, and a 9% increase from Q3's $83 million CAD.Since the company's EPS gain in the last quarter was due mostly to accounting, however, investors should turn their attention to its revenue, EBITDA, and other expenses. For example, other expenses in Q3 included Canopy's share-based compensation more than tripling from CAD $17.8 million to CAD $63.9 million YoY. Its EBITDA loss is mostly due to the temporary nature of the non-producing facilities in the period. Plus, the absorption of the medical excise tax to support customers also contributed to the EBITDA loss.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Canopy Expanding ProductionInvestors are well aware of Canopy's costs related to expanding its facilities to increase production. In Q3, it harvested 7,556 kilograms, which is down from last year, partly due to adjusting for a year-round harvest. Canopy also underwent greenhouse setups and early pilot private harvest in Mirabel in the quarter.Canopy's cash balance surged to CAD $4.9 billion due mostly to Constellation Brands' (NYSE: STZ) November 2018 investment and an aggregate CAD $500 million convertible notes offering. Canopy used the cash to fund operations and for investments and facility enhancements that totaled CAD $568 million year-to-date.Canopy ramped up inventory and biological assets by 100% year-over-year to CAD $185 million. In normal circumstances, an inventory build-up is a negative development. But for Canopy, management is deliberately increasing it so it may meet future expected increases in demand. The company expects both legalization in the recreational market and medical customers choosing Canopy's product to drive demand. Acreage Holdings Acquisition ApprovedCanopy announced on June 19 that its shareholders voted overwhelmingly to approve the acquisition of Acreage Holdings (OTCMKTS:ACRGF). In a move towards becoming more of a global company, Canopy will start with growing its footprint in the U.S. with this acquisition -- contingent upon the U.S legalizing marijuana at the federal level. In this even, CGC gains an active owned or contracted hemp operations in seven states. The seven states are California, Colorado, Kentucky, New York, North Carolina, Oregon, and Pennsylvania. With planting now underway, the mixture of high-CBD varieties and high-fibre genetics may supply the raw material necessary for the large-scale production of hemp-based products.Once Canopy reaches full capacity, it will have American farmers contracted to cover over 4000 acres. Half of the farming platform will be located in New York State with high-CBD hemp and high fibre hemp growth making up much of the production.When Canopy's facilities are all up and running, investors should expect continued improvements in yields and utilization. CGC stock's quarterly earnings report will start showing better margins as yields increase. In the short term, which includes results from the upcoming earnings report, expect costs exceeding revenue. Margins will not get to the mid-50 range for another five to seven quarters. The company is implementing a business plan that is not about selling medical marijuana alone. It is now selling a product based on the outcome of cannabinoid therapy. And studies and various trials validating those therapies take time. Valuation on CGC Stock and Your TakeawayAnalysts are highly bullish on Canopy Growth stock. 11 analysts have an average price target of $80, which represents a potential return of 87% based on a recent closing price of $42.77. * 6 Stocks Ready to Bounce on a Trade Deal CGC stock will need to continue growing revenue at a 300% year-over-year pace to justify a $20 billion valuation. If its yields increase in the next few quarters, then the positive earnings will validate Constellation Brands' big $4 billion bet on the company.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal Compare Brokers The post The Short-Term Earnings Numbers for CGC Stock Aren't Most Important appeared first on InvestorPlace.

  • Aurora’s Strategic Decisions Make It Difficult to Profit From Aurora Stock
    InvestorPlace6 days ago

    Aurora’s Strategic Decisions Make It Difficult to Profit From Aurora Stock

    Aurora Cannabis (NYSE:ACB) faces a conundrum. The company continues to make key acquisitions. that have increased its production capacity. As a result, Aurora has become the largest producer of cannabis, but issues with ACB stock itself should make investors pause before buying the shares. Given the company's finances, investors might want to buy other marijuana stocks besides Aurora.In a recent article, I stated that the market has correctly given ACB stock a lower valuation than that of its peers. Its price-sales ratio of just above 61 lags that of Canopy Growth (NYSE:CGC), Tilray (NASDAQ:TLRY), and Cronos Group (NASDAQ:CRON). Aurora Is the Leading Producer of CannabisAurora has excelled in some areas. Its purchase of MedReLeaf raised its production capacity to an estimated level of 570,000 kg. That placed ACB ahead of the company seen as the industry leader, Canopy Growth. Some have also speculated that Aurora Cannabis will become the first company to reach the 1 million kg per year mark.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 6 Stocks Ready to Bounce on a Trade Deal Aurora also made a key move in the increasingly important Latin American market last year. In November, Aurora acquired Uruguay-based ICC Labs for around C$290 million ($216.7 million). That does not sound like a huge deal on the surface. However, it gives Aurora a 70% market share in Uruguay, the first country to fully legalize marijuana. Through the deal, Aurora also obtained licenses to produce medical marijuana in Colombia and export CBD products to Mexico. Strategic, Financial Issues Weigh on ACB StockUnfortunately, analysts have defined Aurora Cannabis stock by what the company has not done. Since it lacks a presence in the U.S. hemp industry or a partnership with a huge company, such as the one Canopy Growth has with Constellation Brands (NYSE:STZ), ACB stock has not commanded the premiums of its large peers.ACB stock is facing other problems. Other InvestorPlace columnists have pointed out that the company has a large amount of goodwill from various acquisitions. The company reported $3.177 billion of goodwill as of the last quarter. This constitutes a majority of the $5.55 billion of total assets on its balance sheet.The dilution of ACB stock also raises some red flags. The shares of Aurora stock outstanding have risen from about 129 million in 2016 to just over 1 billion today. That has kept its long-term debt at a relatively modest $418 million. However, the increased share count makes it much harder for Aurora to increase its earnings per share.The higher share count also makes it harder to profit from ACB stock. Do Not Invest in ACB Stock Because of Its "Number Two" StatusACB stock trades at about $7.50 per share as of the time of this writing. Despite this, traders tend to think of Aurora Cannabis as the second-largest marijuana company. In most cases, I agree with Jack Welch's strategy regarding second-place companies. When he was the head of GE (NYSE:GE), Welch preferred to buy the number one or number two company in an industry. However, after the massive dilution, Aurora stock is a second-place company I would rather avoid.In this sector, I see CGC as the stock of choice among the more prominent names. Alternatively, I would look to either Aphria (NYSE:APHA) or Hexo (NYSEAMERICAN:HEXO), two up-and-coming marijuana stocks which trade at lower valuations. Also, unlike ACB stock, analysts believe these two companies will earn a profit next year. Final Thoughts on ACB StockAurora Cannabis stock should be avoided. With its lead in production capacity and its dominance in Uruguay, I expect the company to survive. However, the stocks of companies that barely manage to survive usually don't rise.Unfortunately, ACB's fundamentals aren't strong enough to lift Aurora stock much. Both its balance sheet and the massive dilution of ACB stock give investors few reasons to have confidence in Aurora. Instead of buying ACB stock , traders would be better served by buying other firms in the cannabis space.As of this writing, Will Healy is long APHA stock. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal Compare Brokers The post Aurora's Strategic Decisions Make It Difficult to Profit From Aurora Stock appeared first on InvestorPlace.